Dexmedetomidine administration reduced mortality in patients with acute respiratory distress syndrome: a propensity score-matched cohort analysis
Authors:
Open Access
- 17 April 2025
- journal article
- medicine
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 12, 1565098
Abstract
Background: Acute respiratory distress syndrome (ARDS) continues to pose significant difficulties due to the scarcity of successful preventative and therapeutic measures. Recent clinical trials and experimental research have confirmed the lung-protective and anti-inflammatory properties of dexmedetomidine. The objective of this study was to examine the relationship between the use of dexmedetomidine and mortality outcomes in ICU patients with ARDS.Methods: This study retrospectively examined data from the Medical Information Mart for Intensive Care (MIMIC) IV, focusing on individuals diagnosed with ARDS. The primary endpoint was the occurrence of death within 28 days after entering the ICU. To ensure a balanced cohort, we applied propensity score matching at a 1:1 ratio. Additionally, multivariable analysis was performed to mitigate the effects of confounding factors.Results: In this study, a cohort comprising 612 patients diagnosed with ARDS was investigated. Analysis using both univariate and multivariate Cox regression indicated significantly reduced 28-day and 90-day mortality rates in patients administered dexmedetomidine compared to those who were not given this treatment. Following adjustments for potential confounders using propensity score matching, these results were confirmed to be robust.Conclusion: The results indicate an association between the administration of dexmedetomidine and lower mortality rates among severely ill ARDS patients. However, this result should be interpreted with cause because of a lot of missing data of potential risk factors for clinical outcomes. Nonetheless, it is imperative to perform further randomized controlled trials to corroborate this finding.Keywords
This publication has 38 references indexed in Scilit:
- ESICM guidelines on acute respiratory distress syndrome: definition, phenotyping and respiratory support strategiesIntensive Care Medicine, 2023
- MicroRNA-214–5p involves in the protection effect of Dexmedetomidine against neurological injury in Alzheimer’s disease via targeting the suppressor of zest 12Brain Research Bulletin, 2022
- Dexmedetomidine exerts cerebral protective effects against cerebral ischemic injury by promoting the polarization of M2 microglia via the Nrf2/HO-1/NLRP3 pathwayInflammation Research, 2021
- The Epidemiology of Acute Respiratory Distress Syndrome Before and After Coronavirus Disease 2019Critical Care Clinics, 2021
- Adrenergic regulation of immune cell function and inflammationSeminars in Immunopathology, 2020
- Dexmedetomidine ameliorates LPS induced acute lung injury via GSK-3β/STAT3-NF-κB signaling pathway in ratsInternational Immunopharmacology, 2019
- Acute Respiratory Distress SyndromeJAMA, 2018
- Epidemiology, Patterns of Care, and Mortality for Patients With Acute Respiratory Distress Syndrome in Intensive Care Units in 50 CountriesJAMA, 2016
- Dexmedetomidine: A Review of Its Use for Sedation in the Intensive Care SettingDrugs, 2015
- The Berlin definition of ARDS: an expanded rationale, justification, and supplementary materialIntensive Care Medicine, 2012